Pulmonary disease
Conditions
Interventions
Group 1:Remazolam for common bronchoscopy
Group 2:Propofol for general bronchoscopy
Group 3:Remazolam for complex bronchoscopy anesthesia
Group 4:Propofol for complex bronchoscopy anesthesia
Sponsors
National Cancer Center (Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years; 2. Patients who were scheduled to undergo bronchoscopy (divided into ordinary and complex endoscopic patients); 3. Agree to be tested and sign informed consent; 4. ASA I-III.
Exclusion criteria
Exclusion criteria: 1. A history of acute inflammation of the respiratory tract that has not been cured within one week; 2. Patients with severe respiratory diseases; 3. Mental disorder; 4. Difficulty in respiratory management (Mallampati grade IV); 5. Have a history of drug abuse; 6. Those who have used benzodiazepines continuously for more than 3 months; 7. BMI 31; 8. Liver and kidney insufficiency; 9. Heart insufficiency; 10. Those with contraindications to the drug application in the study; 11. Patients who have participated in other medical studies in the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of hypoxemia;BPS(Behavioral Pain Scale) analgesia score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dosage of remazolam, fentanyl and propofol and times of addition;The nasal EtCO2;Respiratory rate;Awakening time;MOAA(modified observer's assessment of alert)/S Sedation and wakefulness score; | — |
Countries
China
Contacts
Public ContactZheng Hui
National Cancer Center (National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College)
Outcome results
None listed